Global Milbemycin Oxime API Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031
Description
According to our (Global Info Research) latest study, the global Milbemycin Oxime API market size was valued at US$ 228 million in 2024 and is forecast to a readjusted size of USD 347 million by 2031 with a CAGR of 6.3% during review period.
Milbemycin is a new type of semi-synthetic macrolide anthelmintic. It is an oxime derivative of Milbemycin A3 and A4. The molecular weight of A3 oxime is 541.7, and the molecular weight of A4 oxime is 555.7. In terms of application, milbexime can be used alone or in combination with nitenpyram, lufenuron, spinosad, praziquantel, etc. to form a compound preparation, which can effectively prevent and control heartworms, hookworms, roundworms, whipworms, roundworms and other internal parasites, as well as hair follicles, scabies, lice, fleas and other external parasites. Milbexime acts as an agonist of the GABA (gamma-aminobutyric acid) neurotransmitter in nerve cells and also binds to glutamate-gated Cl– channels in invertebrate nerve and muscle cells. In both cases, it blocks the parasites nerve signaling, eventually paralyzing the parasite, causing the muscles to lose their ability to contract, stop feeding, and cause the parasite to die.
Global 3 largest manufacturers of Milbemycin Oxime API are Livzon Pharmaceutical Group Inc, Zhejiang Hisun Pharmaceutical Co., Ltd and Hubei Honch Pharmaceutical Co.,Ltd, which make up over 40%. Among them, Livzon Pharmaceutical Group Inc is the leader with about 22% market share. North America is the largest market, with a share about 48%, followed by Europe and China, with the share about 46% and 2%. In terms of product type, Purity Greater than 98% occupy the largest share of the total market, about 85%. And in terms of product Application, the largest application is Dog, followed by Cat.
This report is a detailed and comprehensive analysis for global Milbemycin Oxime API market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Milbemycin Oxime API market size and forecasts, in consumption value ($ Million), sales quantity (KG), and average selling prices (US$/KG), 2020-2031
Global Milbemycin Oxime API market size and forecasts by region and country, in consumption value ($ Million), sales quantity (KG), and average selling prices (US$/KG), 2020-2031
Global Milbemycin Oxime API market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (KG), and average selling prices (US$/KG), 2020-2031
Global Milbemycin Oxime API market shares of main players, shipments in revenue ($ Million), sales quantity (KG), and ASP (US$/KG), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Milbemycin Oxime API
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Milbemycin Oxime API market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Livzon Pharmaceutical Group Inc, Zhejiang Hisun Pharmaceutical Co., Ltd, Hubei Honch Pharmaceutical Co.,Ltd, JIANGSU LINGYUN PHARMACEUTICAL CO.，LTD, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Milbemycin Oxime API market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
98% Purity
Purity Greater than 98%
Market segment by Application
Dog
Cat
Other
Major players covered
Livzon Pharmaceutical Group Inc
Zhejiang Hisun Pharmaceutical Co., Ltd
Hubei Honch Pharmaceutical Co.,Ltd
JIANGSU LINGYUN PHARMACEUTICAL CO.，LTD
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Milbemycin Oxime API product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Milbemycin Oxime API, with price, sales quantity, revenue, and global market share of Milbemycin Oxime API from 2020 to 2025.
Chapter 3, the Milbemycin Oxime API competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Milbemycin Oxime API breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Milbemycin Oxime API market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Milbemycin Oxime API.
Chapter 14 and 15, to describe Milbemycin Oxime API sales channel, distributors, customers, research findings and conclusion.
Milbemycin is a new type of semi-synthetic macrolide anthelmintic. It is an oxime derivative of Milbemycin A3 and A4. The molecular weight of A3 oxime is 541.7, and the molecular weight of A4 oxime is 555.7. In terms of application, milbexime can be used alone or in combination with nitenpyram, lufenuron, spinosad, praziquantel, etc. to form a compound preparation, which can effectively prevent and control heartworms, hookworms, roundworms, whipworms, roundworms and other internal parasites, as well as hair follicles, scabies, lice, fleas and other external parasites. Milbexime acts as an agonist of the GABA (gamma-aminobutyric acid) neurotransmitter in nerve cells and also binds to glutamate-gated Cl– channels in invertebrate nerve and muscle cells. In both cases, it blocks the parasites nerve signaling, eventually paralyzing the parasite, causing the muscles to lose their ability to contract, stop feeding, and cause the parasite to die.
Global 3 largest manufacturers of Milbemycin Oxime API are Livzon Pharmaceutical Group Inc, Zhejiang Hisun Pharmaceutical Co., Ltd and Hubei Honch Pharmaceutical Co.,Ltd, which make up over 40%. Among them, Livzon Pharmaceutical Group Inc is the leader with about 22% market share. North America is the largest market, with a share about 48%, followed by Europe and China, with the share about 46% and 2%. In terms of product type, Purity Greater than 98% occupy the largest share of the total market, about 85%. And in terms of product Application, the largest application is Dog, followed by Cat.
This report is a detailed and comprehensive analysis for global Milbemycin Oxime API market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Milbemycin Oxime API market size and forecasts, in consumption value ($ Million), sales quantity (KG), and average selling prices (US$/KG), 2020-2031
Global Milbemycin Oxime API market size and forecasts by region and country, in consumption value ($ Million), sales quantity (KG), and average selling prices (US$/KG), 2020-2031
Global Milbemycin Oxime API market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (KG), and average selling prices (US$/KG), 2020-2031
Global Milbemycin Oxime API market shares of main players, shipments in revenue ($ Million), sales quantity (KG), and ASP (US$/KG), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Milbemycin Oxime API
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Milbemycin Oxime API market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Livzon Pharmaceutical Group Inc, Zhejiang Hisun Pharmaceutical Co., Ltd, Hubei Honch Pharmaceutical Co.,Ltd, JIANGSU LINGYUN PHARMACEUTICAL CO.，LTD, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Milbemycin Oxime API market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
98% Purity
Purity Greater than 98%
Market segment by Application
Dog
Cat
Other
Major players covered
Livzon Pharmaceutical Group Inc
Zhejiang Hisun Pharmaceutical Co., Ltd
Hubei Honch Pharmaceutical Co.,Ltd
JIANGSU LINGYUN PHARMACEUTICAL CO.，LTD
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Milbemycin Oxime API product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Milbemycin Oxime API, with price, sales quantity, revenue, and global market share of Milbemycin Oxime API from 2020 to 2025.
Chapter 3, the Milbemycin Oxime API competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Milbemycin Oxime API breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Milbemycin Oxime API market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Milbemycin Oxime API.
Chapter 14 and 15, to describe Milbemycin Oxime API sales channel, distributors, customers, research findings and conclusion.
Table of Contents
71 Pages
- 1 Market Overview
- 2 Manufacturers Profiles
- 3 Competitive Environment: Milbemycin Oxime API by Manufacturer
- 4 Consumption Analysis by Region
- 5 Market Segment by Type
- 6 Market Segment by Application
- 7 North America
- 8 Europe
- 9 Asia-Pacific
- 10 South America
- 11 Middle East & Africa
- 12 Market Dynamics
- 13 Raw Material and Industry Chain
- 14 Shipments by Distribution Channel
- 15 Research Findings and Conclusion
- 16 Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
